Revance's New Strategy: A Two-Pronged Attack on Acne and Scars

NASHVILLE, TN – June 01, 2026 – Revance is launching a new, unified front in the battle against acne this month, combining two of its leading brands, PanOxyl and SkinPen, into a single, comprehensive campaign. The initiative, timed for Acne Awareness Month, aims to address what the company calls a "holistic approach" to acne care, targeting not just active breakouts but also the persistent scars they often leave behind.

This move signals a significant strategic play by the aesthetics and therapeutics company to create a complete consumer journey, from initial treatment to long-term skin recovery.

A Full-Circle Solution for a Persistent Problem

For millions of consumers, the acne journey doesn't end when a blemish fades. The emotional and physical aftermath, particularly in the form of facial acne scars, can have a lasting impact. Revance's new campaign directly confronts this reality by pairing PanOxyl, a powerhouse in treating active acne, with SkinPen, a leading medical device for improving the appearance of scars.

PanOxyl has built a formidable reputation over its 50-year heritage. Backed by recent data, it stands as the #1 dermatologist-recommended benzoyl peroxide brand and the #1 best-selling acne wash in the United States. Its formulas, which include active ingredients like benzoyl peroxide, salicylic acid, and adapalene, are designed to clear existing acne and prevent new breakouts.

"Acne can have a significant emotional impact on confidence at every age and stage of life," said Steve Gallopo, EVP & Chief Commercial Officer of Consumer Skincare for Crown Laboratories, Inc., a Revance Company. "This campaign is about helping consumers feel supported throughout their skincare journey and empowering them with trusted solutions from PanOxyl that help them put their best face forward."

Once the active acne is managed, the campaign transitions the focus to SkinPen. Recognized as the #1 brand in microneedling pens in the U.S., SkinPen was the first device of its kind to receive FDA clearance for treating the appearance of facial acne scars. The treatment works by creating controlled micro-injuries to stimulate the body's natural wound-healing process, promoting skin regeneration. This approach is suitable for all skin types and can be performed year-round, offering a versatile solution for the lingering visible effects of acne.

This dual strategy aligns perfectly with a major shift in consumer behavior. The modern skincare enthusiast is increasingly moving away from single-product fixes and toward integrated, multi-step routines that address skin health comprehensively. The market for scar and acne-scar remodeling is one of the fastest-growing segments in skin rejuvenation, underscoring a strong demand for the very solutions SkinPen provides.

Revance's Strategic Synergy in a Crowded Market

The partnership between PanOxyl and SkinPen is more than a consumer-facing initiative; it's a calculated business strategy designed to fortify Revance's position in the highly competitive dermatology and aesthetics market. While competitors like Galderma and Johnson & Johnson offer powerful acne treatments, and companies like Merz Aesthetics provide advanced skin rejuvenation devices, Revance's campaign is unique in its explicit marketing of an integrated journey under a single corporate umbrella.

This synergy allows Revance to leverage the significant brand equity of two market leaders. By creating a seamless narrative that connects an over-the-counter solution with a professional in-office procedure, the company can capture consumers at multiple points in their treatment process and guide them through a complete product ecosystem.

This move is particularly strategic for Revance Therapeutics, Inc. (NASDAQ: RVNC), a company that has been making headlines with its aesthetic injectables, including the neuromodulator DAXXIFY and the RHA Collection of dermal fillers. While those products are central to its financial performance, this campaign demonstrates a broader vision. It diversifies the company's focus, strengthens its consumer skincare division, and showcases its ability to build a comprehensive portfolio that addresses a wide range of aesthetic concerns.

"With SkinPen, we are committed to advancing innovative solutions that address the lasting visible effects of acne," said Curry Smith, Executive Marketing Director of Regenerative Aesthetics at Revance. "Our technology is built to support providers and patients with a reliable, year-round option that fits seamlessly into a comprehensive approach to facial acne scar care."

Expert Voices and the Power of a Complete Narrative

To bolster the campaign's credibility and reach, Revance has enlisted a team of medical professionals and a social media influencer. The collaboration features board-certified plastic surgeon Dr. Michelle Lee, board-certified dermatologist Dr. Suneel Chilukuri, and influencer Bridget Campbell. This multi-pronged approach aims to deliver the campaign's message through both trusted medical authorities and relatable personal stories.

Dr. Chilukuri, who has previously endorsed PanOxyl, lends significant dermatological weight to the partnership. His involvement underscores the medical validity of using these solutions in tandem. "Acne is a journey that extends beyond active breakouts, often leaving behind visible reminders long after acne has cleared," stated Dr. Suneel Chilukuri. "By pairing PanOxyl's trusted acne care options with SkinPen's approach to improving the appearance of facial acne scars, we're able to support patients through multiple stages of their skincare journey with complementary solutions that address both treatment and recovery."

The inclusion of a plastic surgeon and an influencer further broadens the campaign's appeal, connecting the technical aspects of scar revision with the real-world desire for aesthetic improvement and confidence. This educational focus is a key component, aiming to foster greater awareness about the available treatment pathways for one of the most common skin conditions worldwide.

Driving Access with Timely Promotions

To encourage consumers to embark on this comprehensive journey, Revance is backing the campaign with significant promotions throughout June. For those considering professional treatment, SkinPen is highlighting its "$100 Reasons to Love SkinPen" rebate program, offering a $100 digital gift card to eligible patients who purchase a series of three or more treatments before the end of the month.

Simultaneously, PanOxyl is launching its first-ever Amazon promotion, offering a 20% discount on any of its products for the entire month. This move significantly lowers the barrier to entry for consumers seeking effective, dermatologist-recommended at-home care. The company advises that PanOxyl should not be used within 24 hours of a SkinPen treatment, reinforcing the importance of following proper protocols when combining at-home and professional care.

By coupling a powerful marketing narrative with tangible financial incentives and expert validation, Revance is making a compelling case for its end-to-end acne care strategy, aiming to become the definitive solution for consumers navigating the complex journey from active breakouts to clear, confident skin.